Anti-RPL36A-HNRNPH2 monoclonal antibody

Anti-RPL36A-HNRNPH2 antibody for FACS & in-vivo assay

Target products collectionGo to RPL36A-HNRNPH2/RPL36A-HNRNPH2 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-MP2310-Ab-1/ GM-Tg-hg-MP2310-Ab-2Anti-Human RPL36A-HNRNPH2 monoclonal antibodyHuman
GM-Tg-rg-MP2310-Ab-1/ GM-Tg-rg-MP2310-Ab-2Anti-Rat RPL36A-HNRNPH2 monoclonal antibodyRat
GM-Tg-mg-MP2310-Ab-1/ GM-Tg-mg-MP2310-Ab-2Anti-Mouse RPL36A-HNRNPH2 monoclonal antibodyMouse
GM-Tg-cynog-MP2310-Ab-1/ GM-Tg-cynog-MP2310-Ab-2Anti-Cynomolgus/ Rhesus macaque RPL36A-HNRNPH2 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-MP2310-Ab-1/ GM-Tg-felg-MP2310-Ab-2Anti-Feline RPL36A-HNRNPH2 monoclonal antibodyFeline
GM-Tg-cang-MP2310-Ab-1/ GM-Tg-cang-MP2310-Ab-2Anti-Canine RPL36A-HNRNPH2 monoclonal antibodyCanine
GM-Tg-bovg-MP2310-Ab-1/ GM-Tg-bovg-MP2310-Ab-2Anti-Bovine RPL36A-HNRNPH2 monoclonal antibodyBovine
GM-Tg-equg-MP2310-Ab-1/ GM-Tg-equg-MP2310-Ab-2Anti-Equine RPL36A-HNRNPH2 monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-MP2310-Ab-1/ GM-Tg-hg-MP2310-Ab-2; GM-Tg-rg-MP2310-Ab-1/ GM-Tg-rg-MP2310-Ab-2;
GM-Tg-mg-MP2310-Ab-1/ GM-Tg-mg-MP2310-Ab-2; GM-Tg-cynog-MP2310-Ab-1/ GM-Tg-cynog-MP2310-Ab-2;
GM-Tg-felg-MP2310-Ab-1/ GM-Tg-felg-MP2310-Ab-2; GM-Tg-cang-MP2310-Ab-1/ GM-Tg-cang-MP2310-Ab-2;
GM-Tg-bovg-MP2310-Ab-1/ GM-Tg-bovg-MP2310-Ab-2; GM-Tg-equg-MP2310-Ab-1/ GM-Tg-equg-MP2310-Ab-2
Products NameAnti-RPL36A-HNRNPH2 monoclonal antibody
Formatmab
Target NameRPL36A-HNRNPH2
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-RPL36A-HNRNPH2 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenProducts DevelopingMulti-species RPL36A-HNRNPH2 VLP (virus-like particle) (Products Developing)


    Target information

    Target IDGM-MP2310
    Target NameRPL36A-HNRNPH2
    Gene ID100529097
    Gene Symbol and SynonymsRPL36A-HNRNPH2
    Uniprot AccessionN/A
    Uniprot Entry Name
    Protein Sub-locationTransmembrane Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000257529
    Target ClassificationN/A

    The target: RPL36A-HNRNPH2, gene name: RPL36A-HNRNPH2, also named as . This locus represents naturally occurring read-through transcription between the neighboring ribosomal protein L36a and heterogeneous nuclear ribonucleoprotein H2 (H') genes on chromosome X. The read-through transcript produces a protein with similarity to the protein encoded by the upstream locus, ribosomal protein L36a. Alternatively spliced transcript variants have been identified. [provided by RefSeq, Jan 2011].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.